Renhua Guo

4.9k total citations · 2 hit papers
99 papers, 2.6k citations indexed

About

Renhua Guo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Renhua Guo has authored 99 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Pulmonary and Respiratory Medicine, 59 papers in Oncology and 38 papers in Cancer Research. Recurrent topics in Renhua Guo's work include Lung Cancer Treatments and Mutations (51 papers), Colorectal Cancer Treatments and Studies (18 papers) and Lung Cancer Research Studies (18 papers). Renhua Guo is often cited by papers focused on Lung Cancer Treatments and Mutations (51 papers), Colorectal Cancer Treatments and Studies (18 papers) and Lung Cancer Research Studies (18 papers). Renhua Guo collaborates with scholars based in China, United States and Norway. Renhua Guo's co-authors include Shidai Jin, Xinyin Liu, Chen Zhang, Yi Chen, Erbao Zhang, Xiyi Lu, Wei Wang, Dandan Yin, Zhihong Zhang and Tianyu Qu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Renhua Guo

94 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ferroptosis in cancer therapy: a novel approach to reversing drug resistance

2022 907 citations Chen Zhang, Xinyin Liu et al. profile →
NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer

2025 17 citations Xiyi Lu, Tianyu Qu et al. profile →

Peers

Countries citing papers authored by Renhua Guo

Since Specialization

Citations

This map shows the geographic impact of Renhua Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renhua Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renhua Guo more than expected).

Fields of papers citing papers by Renhua Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renhua Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renhua Guo. The network helps show where Renhua Guo may publish in the future.

Co-authorship network of co-authors of Renhua Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Renhua Guo. A scholar is included among the top collaborators of Renhua Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renhua Guo. Renhua Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study 2025 ·Cancer Science ·(unknown), (unknown), Yuting Zhu, Xiao Liang, Rong Huang, Wenxin Zhou, Chen Zhang, Jun Li, Jiali Xu, Renhua Guo	0
2	Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer 2024 ·JCO Precision Oncology ·Huaying Wang, (unknown), (unknown), (unknown), Jiani C. Yin, Junli Zhang, (unknown), Chengming Sun, Renhua Guo	1
3	Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer 2024 ·Molecular Carcinogenesis ·Liang Xiao, Jiali Xu, (unknown), (unknown), Hongshuai Wu, (unknown), Yanan Cui, Chen Zhang, Wei Chen, Zhihong Zhang, Renhua Guo	2
4	Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer 2023 ·Oxidative Medicine and Cellular Longevity ·(unknown), Xiyi Lu, Xinyin Liu, Jiali Xu, (unknown), (unknown), (unknown), Renhua Guo	14
5	Safety, efficacy, and pharmacokinetics of SH‐1028 in EGFR T790M‐positive advanced non–small cell lung cancer patients: A dose‐escalation phase 1 study 2023 ·Cancer ·Jing He, Pei Ma, Dongmei Zhao, (unknown), Renhua Guo, Wen Gao, Yongqian Shu	5
6	Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients 2023 ·Oncology Letters ·(unknown), (unknown), Xiaowen Liang, Nan Chen, Yun Chen, Chen Zhang, Junfeng Shi, Renhua Guo	3
7	LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer 2023 ·Cell Death and Disease ·(unknown), Tianyu Qu, Dandan Yin, Yanan Cui, Chen Zhang, Erbao Zhang, Renhua Guo	65
8	B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma 2023 ·Journal of Experimental & Clinical Cancer Research ·Yanan Cui, Jun Li, Pengpeng Zhang, Dandan Yin, Ziyu Wang, (unknown), Wei Wang, Erbao Zhang, Renhua Guo	41
9	MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc–Mediated Cell-Cycle Progression and Proliferation in Lung Cancer 2022 ·Cancer Research ·Qingqing Zhu, Chongguo Zhang, Tianyu Qu, Xiyi Lu, Xuezhi He, (unknown), Dandan Yin, Liang Han, Renhua Guo, Erbao Zhang	65
10	Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer 2022 ·Frontiers in Oncology ·Yanan Cui, Xinyin Liu, (unknown), Liang Xiao, (unknown), Zhihong Zhang, Renhua Guo	8
11	High Expression of ACE2 and TMPRSS2 at the Resection Margin Makes Lung Cancer Survivors Susceptible to SARS-CoV-2 With Unfavorable Prognosis 2021 ·Frontiers in Oncology ·Qianqian Wang, (unknown), Tianyu Qu, (unknown), Lingxiang Wu, Kening Li, Ziyu Wang, Mengyan Zhu, Bin Huang, Wei Wu, Min Wu, Rong Ding, Zhihong Zhang, (unknown), Qianghu Wang, Xinyi Xia, Pengping Li, Zhi Zhang, Renhua Guo	16
12	Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting 2021 ·BMC Cancer ·Qianqian Wang, Wen Gao, Fangyan Gao, Shidai Jin, Tianyu Qu, Fan Lin, Chen Zhang, Jingya Zhang, Zhihong Zhang, Liang Chen, Renhua Guo	9
13	LEMD1-AS1 Suppresses Ovarian Cancer Progression Through Regulating miR-183-5p/TP53 Axis 2020 ·SHILAP Revista de lepidopterología ·Renhua Guo, (unknown)	1
14	1267P Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC 2020 ·Annals of Oncology ·(unknown), (unknown), Shengxiang Ren, Jun Zhao, G. Chen, (unknown), Kangsheng Gu, Renhua Guo, Yueyin Pan, (unknown), C.Z. Zhou	2
15	Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study 2019 ·Frontiers in Oncology ·(unknown), Yiqian Liu, Ann‐Kathrin Eisfeld, Fuxi Zhen, Shidai Jin, Wen Gao, Tongfu Yu, Liang Chen, Wei Wang, Wei Chen, Mingming Yuan, Rongrong Chen, Kai He, Renhua Guo	35
16	P1.01-105 Lung Cancer Patients with Concurrent EGFR and MET Mutations: A Retrospective Analysis of 29 Cases 2018 ·Journal of Thoracic Oncology ·(unknown), Mei Yuan, Renhua Guo, Gen Lin, (unknown), Xiaorong Dong, (unknown), (unknown)	0
17	Clinicopathological significance of ROCK1 and PIK3CA expression in nasopharyngeal carcinoma 2017 ·Experimental and Therapeutic Medicine ·Xuanyi Wang, Yuxiang Huang, Renhua Guo, Yong-Biao Liu, Yayun Qian, Dan Liu, Xiaojun Dai, Wei Zheng, Feng Jin, Yanqing Liu	9
18	A novel long noncoding RNA IRAIN regulates cell proliferation in non small cell lung cancer. 2015 ·PubMed Central ·Jing Feng, Yue Sun, Erbao Zhang, Xiyi Lu, Shidai Jin, Renhua Guo	22
19	Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review 2013 ·PLoS ONE ·Xiaofeng Chen, Yiqian Liu, Oluf Dimitri Røe, Yingying Qian, Renhua Guo, Lingjun Zhu, Yongmei Yin, Yongqian Shu	50
20	Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib 2012 ·Biomedicine & Pharmacotherapy ·(unknown), Hua Shen, Renhua Guo, Jing Sun, Wen Gao, Yongqian Shu	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact